A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

Inclusion Criteria:

• Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior tothe first administration of study intervention

• Total body surface area (BSA) greater than or equal to (>=)10 percent (%) atscreening and baseline

• Total psoriasis area and severity index (PASI) >=12 at screening and baseline

• Total investigator global assessment (IGA) >=3 at screening and baseline

• Candidate for phototherapy or systemic treatment for plaque psoriasis

Exclusion Criteria:

• Nonplaque form of psoriasis (for example [e.g.], erythrodermic, guttate, orpustular)

• Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation ofpsoriasis from beta blockers, calcium channel blockers, or lithium)

• Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, orits excipients

• Major surgical procedure within 8 weeks before screening, or will not have fullyrecovered from surgical procedure, or has a surgical procedure planned during thetime the participant is expected to participate in the study

• Transplanted organ (with exception of a corneal transplant greater than [>] 12 weeksbefore the first administration of study intervention)